1
|
Eyileten C, Skrobucha A, Starczyński M, Boszko M, Jarosz-Popek J, Fitas A, Filipiak KJ, Kochman J, Huczek Z, Rymuza B, Wilimski R, Kuśmierczyk M, Siller-Matula JM, Postula M, Gąsecka A. Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation. Cardiol J 2022; 31:111-123. [PMID: 36200549 PMCID: PMC10919566 DOI: 10.5603/cj.a2022.0090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 07/14/2022] [Accepted: 08/05/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at increased surgical risk. Up to 29% of patients annually experience major adverse cardiac and cerebrovascular events (MACCE) after TAVI. MicroRNAs (miRNA) are currently widely investigated as novel cardiovascular biomarkers. The aim of this study was to determine the influence of TAVI on the expressions of selected miRNAs associated with platelet function (miR-125a-5p, miR-125b and miR-223), and evaluate the predictive value of these miRNAs for MACCE in 65 patients undergoing TAVI. METHODS Venous blood samples for miRNA expression analysis were collected 1 day before TAVI and at hospital discharge. The expression of miR-223, miR-125a-5p, miR-125b was evaluated in platelet-depleted plasma. RESULTS The expression of miR-223 and miR-125b increased after TAVI, compared to the measurement before (p = 0.020, p = 0.003, respectively). Among 63 patients discharged from the hospital, 18 patients experienced MACCE (29%) during the median 15 months of observation. Baseline low miR-223 expression was a predictor of MACCE in univariate Cox regression analysis (hazard ratio [HR]: 2.71, 95% confidence interval [CI]: 1.04-7.01; p = 0.041). After inclusion of covariates, age, gender (male), New York Heart Association class and diabetes into the multivariate Cox regression model, miR-223 did not reach statistical significance (HR: 2.56, 95% CI: 0.79-8.33; p = 0.118). CONCLUSIONS To conclude, miR-223 might improve risk stratification after TAVI. Further studies are required to confirm the clinical applicability of this promising biomarker.
Collapse
Affiliation(s)
- Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland
| | - Alicja Skrobucha
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Miłosz Starczyński
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Maria Boszko
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Joanna Jarosz-Popek
- Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland
| | - Krzysztof J Filipiak
- Department of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
| | - Janusz Kochman
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Zenon Huczek
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Bartosz Rymuza
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| | - Radosław Wilimski
- Department of Cardiac Surgery, Medical University of Warsaw, Poland.
| | | | - Jolanta M Siller-Matula
- Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland
- Department of Cardiology, Medical University of Vienna, Austria
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland
| | - Aleksandra Gąsecka
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
| |
Collapse
|
2
|
Wicik Z, Czajka P, Eyileten C, Fitas A, Wolska M, Jakubik D, von Lewinski D, Sourij H, Siller-Matula JM, Postula M. The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis. Platelets 2022; 33:1052-1064. [DOI: 10.1080/09537104.2022.2042233] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Zofia Wicik
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| | - Pamela Czajka
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| | - Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| | - Marta Wolska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
- Doctoral School of Medical University of Warsaw, Poland
| | - Daniel Jakubik
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| | - Dirk von Lewinski
- Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria
| | - Harald Sourij
- Division of Endocrinology and Diabetology, Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria
| | - Jolanta M. Siller-Matula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
- Department of Cardiology, Medical University of Vienna, Vienna, Austria
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology Cept, Warsaw, Poland
| |
Collapse
|
3
|
Eyileten C, Wicik Z, Fitas A, Marszalek M, Simon JE, De Rosa S, Wiecha S, Palatini J, Postula M, Malek LA. Altered Circulating MicroRNA Profiles After Endurance Training: A Cohort Study of Ultramarathon Runners. Front Physiol 2022; 12:792931. [PMID: 35145424 PMCID: PMC8824535 DOI: 10.3389/fphys.2021.792931] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 12/21/2021] [Indexed: 12/18/2022] Open
Abstract
Background Despite the positive effects of endurance training on the cardiovascular (CV) system, excessive exercise induces not only physiological adaptations but also adverse changes in CV system, including the heart. We aimed to evaluate the selected miRNAs expression based on bioinformatic analysis and their changes before and after an ultramarathon run. Materials and Methods Cardiac tissue-specific targets were identified with the Tissue 2.0 database. Gene-gene interaction data were retrieved from the STRING app for Cytoscape. Twenty-three endurance athletes were recruited to the study. Athletes ran to completion (100 km) or exhaustion (52–91 km, median 74 km). All participants completed pre- and post-run testing. miRNAs expressions were measured both before and after the race. Results Enrichment analysis of the signaling pathways associated with the genes targeted by miRNAs selected for qRT-PCR validation (miR-1-3p, miR-126, miR-223, miR-125a-5p, miR-106a-5p, and miR-15a/b). All selected miRNAs showed overlap in regulation in pathways associated with cancer, IL-2 signaling, TGF-β signaling as well as BDNF signaling pathway. Analysis of metabolites revealed significant regulation of magnesium and guanosine triphosphate across analyzed miRNA targets. MiR-1-3p, miR-125a-5p, miR-126, and miR-223 expressions were measured in 23 experienced endurance athletes, before and after an ultramarathon wherein athletes ran to completion (100 km) or exhaustion (52–91 km, median 74 km). The expressions of miR-125a-5p, miR-126, and miR-223 were significantly increased after the race (p = 0.007, p = 0.001, p = 0.014, respectively). MiR-1-3p expression post-run showed a negative correlation with the post-run levels of high-sensitivity C-reactive protein (hs-CRP) (r = −0.632, p = 0.003). Higher miR-1-3p expression was found in runners, who finished the race under 10 h compared to runners who finished over 10 h (p = 0.001). Post-run miR-125a-5p expression showed a negative correlation with the peak lactate during the run (r = −0.576, p = 0.019). Conclusion Extreme physical activity, as exemplified by an ultramarathon, is associated with changes in circulating miRNAs’ expression related to inflammation, fibrosis, and cardiac muscle function. In particular, the negative correlations between miR-125a-5p and lactate concentrations, and miR-1-3p and hs-CRP, support their role in specific exercise-induced adaptation. Further studies are essential to validate the long-term effect of these observations.
Collapse
Affiliation(s)
- Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
- Genomics Core Facility, Centre of New Technologies, University of Warsaw, Warsaw, Poland
| | - Zofia Wicik
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Mikolaj Marszalek
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Jenny E. Simon
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
| | - Salvatore De Rosa
- Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
| | - Szczepan Wiecha
- Department of Physical Education and Health in Biala Podlaska, Józef Pilsudski University of Physical Education in Warsaw, Biala Podlaska, Poland
| | - Jeffrey Palatini
- Genomics Core Facility, Centre of New Technologies, University of Warsaw, Warsaw, Poland
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland
- *Correspondence: Marek Postula,
| | - Lukasz A. Malek
- Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
| |
Collapse
|
4
|
Marszalek M, Simon JE, Fitas A, Czajka P, Eyileten C, Wicik Z, De Rosa S, Postula M, Malek L. Altered circulating microRNA profiles after endurance training: an ultramarathon runner cohort study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background and aim
Characterized by prolonged, highly dynamic exercise that is low-to-high power in nature, endurance training has proven beneficial in cardiovascular disease prevention. Several miRNAs have been reported to be regulated in response to exercise in healthy humans. Our aim was to determine the miRNA expression changes before and after an ultramarathon run in elite runners [1].
Method
We performed bioinformatic analyses - tissue-specific/CV process-specific. Each bioinformatic analysis included 55 miRNAs (figure 1). The multiMiR 1.4 R package was used to identify the targets of miRNAs while a screening of the gene ontology terms for the presence of keywords with the biomaRt interface was used to identify genes associated with angiogenesis, cardiac muscle function, muscle hypertrophy, coagulation, inflammation, and fibrosis. Cardiac tissue-specific targets were identified in Tissue 2.0 database using expression confidence score >2. Gene-gene interaction data were retrieved from the STRING app for Cytoscape. Enrichment analyses of biological processes and reactome and KEGG pathways were also conducted on the STRING app. miR-1-3p, miR-126, miR-223, miR-125a-5p, miR-106a, and miR-15a/b were chosen, based on bioinformatic analysis for qRT-PCR validation, among those related to inflammation, fibrosis and cardiac function [2].
Total RNA was extracted from plasma samples using the MirVana PARIS Kit (ABI, California, USA) and quality was assessed using fluorometric assay. qRT-PCR was performed using the TaqMan Advance (ABI, Foster City, California) protocol on a high throughput thermal cycler. The Wilcoxon test was used for paired comparison – before vs after ultramarathon running – and Spearman's Correlation was used for database analysis of miRNA expressions, p<0.05.
Results
MiR-1-3p, miR-126, miR-223, miR-125a-5p, miR-106a, and miR-15a/b expressions were measured in 22 endurance athletes before and after an ultramarathon wherein athletes ran to completion (100 km) or exhaustion (52–91 km, median 74 km). We found that the expressions of miR-125a-5p, miR-126, miR-223 were significantly increased after the ultramarathon (p=0.018; p=0.001; p=0.014, respectively), whereas miR-15b was significantly decreased (p=0.028). No significant difference was observed for miR-1-3p and miR-15a, while miR-106a was not detectable in the circulating plasma (figure 2). Additionally, miR-1-3p expression post-run showed negative correlation with hsCRP levels post-run (r=−0.631, p=0.005). miR-125a-5p expression post-run showed negative correlation with max lactate levels during run (r=−0.759, p=0.004).
Conclusion
Extreme physical activity, as exemplified by an ultramarathon, may have an impact on the expression alterations of miRNAs associated with inflammation, fibrosis, and cardiac muscle function. Further studies will clarify the long-term impact of these observations.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Medical University of Warsaw Figure 1Figure 2. Differences in miRNA expression pre- and post-ultramarathon
Collapse
Affiliation(s)
- M Marszalek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J E Simon
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - Z Wicik
- Universidade Federal do ABC, Centro de Matemática, Computação e Cognição,, Sao Paulo, Brazil
| | - S De Rosa
- Magna Graecia University of Catanzaro, Division of Cardiology, Department of Medical and Surgical Sciences, Catanzaro, Italy
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - L Malek
- Institute of Cardiology, Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, Warsaw, Poland
| | | |
Collapse
|
5
|
Eyileten C, Wicik Z, Jakubik D, Jarosz-Popek J, Czajka P, Jezewski M, Wolska M, Fitas A, Nowak A, Gasecka A, De Rosa S, Postula M. MicroRNAs as disease specific diagnostic biomarkers for neoplastic aetiology-related and inflammatory-related pericardial fluid effusion. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background and aim
Malignant involvement of the pericardium is seen in 1 to 20 percent of autopsies in patients with cancer. The most common metastatic tumor involving the pericardium is lung cancer [1]. We aimed to distinguish the origin of the pericardial fluid effusion (i.e. pericarditis vs cancer) based on miRNAs expression in peripheral blood plasma.
Method
8 patients hospitalized for collection of pericardial fluid with pericardial effusion of neoplastic aetiology (lung cancer). Control group includes 8 patients with effusion of inflammatory aetiology. Plasma RNA was extracted by mirVANAPARISKit and quality of RNA was assessed by fluorometric assay. GEP analysis was performed using the Clariom D pico chips, analysed on the Affymetrix platform. Statistical analysis by TAC software. Additional analyses were performed in and R using Signal information obtained from the TAC output. We performed the following tests using log2 transformed data and all comparison groups (A-F). Additional FDR correction, logistic regression, Mann-whitney t-test was used depending of the variables. We calculated Area under the curve using ROCp R package. Scores were ranging from 0 to 1. Co-expression analysis to identify genes authentically expressed was performed using Spearman correlation (cutoff = 0.9, Rpval = 0.05). In order to identify the targets of DE miRNAs we used our wizbionet R package and previously developed pipelines [2,3]. We performed target screening using multimiR package, selecting top 20% predictions from all available databases.
Results
We analyzed targets for all mature versions, and if DE miR was identified as pre-miR we generated -3p and -5p version for it. We also screened DisgeNet database for genes associated with cancer and pericarditis, we identified 2823 and 157 such genes. After identification of the targets of DE miRNAs we performed data aggregation, summarization and obtained information how many targets overall and targets associated with IS are regulated by each DE miRNA. Additionally we identified top targets regulated by the top miRNAs. MiR-5695, miR-4446-5p, miR-572, miR-3131 and miR-4784 were found the most significantly differentially expressed miRNAs in blood plasma for patients with malignancy compared to pericarditis. MiR-22-3p, miR-642a, miR-6771, miR-140-3p, and miR660-5p were found the most significantly differentially expressed miRNAs in pericardial fluid plasma for patients with malignancy compared to pericarditis. Importantly, miR-500b, miR-5188, miR-490, miR-24-3p, miR-383-3p were found the most promising differentially diagnostic biomarkers for malignancy and inflammatory-related pericardial fluid effusion.
Conclusions
For the first time our results indicate the differentially diagnostic power of miRNAs based on comparison of circulating in peripheral blood and pericardial fluid in patients having excessive pericardial fluid effusion due to different etiologies.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - Z Wicik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - D Jakubik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J Jarosz-Popek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Jezewski
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Wolska
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Nowak
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Gasecka
- Medical University of Warsaw, 1st Chair and Department of Cardiology, Warsaw, Poland
| | - S De Rosa
- Magna Graecia University of Catanzaro, Division of Cardiology, Department of Medical and Surgical Sciences, Catanzaro, Italy
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | | |
Collapse
|
6
|
Eyileten C, Jarosz-Popek J, Jakubik D, Wolska M, Fitas A, Czajka P, Nowak A, Ufnal M, Postula M, Toma A, Lang I, Siller-Matula JM. High concentrations of plasma trimethylamine-n-oxide is associated with long-term cardiovascular mortality in patients with acute coronary syndrome. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Acute coronary syndrome (ACS) remains a leading cause of mortality worldwide [1]. Patients who experienced ACS are at high risk of future cardiovascular events and death [2–4]. Identification of reliable predictive tools could potentially improve the risk stratification [5]. Numerous studies revealed that intestinal microbial organisms (microbiota) and its metabolites, as TMAO (trimethylamine-N-oxide) may play a pathogenic role in a cardiovascular disease (CVD) and ACS [6]. Elevated concentration of circulating TMAO has been associated with increased risk of CVD and major adverse cardiac events (MACE), including myocardial infarction (MI), stroke, major bleeding and all-cause mortality [7].
Purpose
To investigate the association of liver metabolite TMAO with cardiovascular disease (CV)-related and all-cause mortality in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention.
Methods
Our prospective observational study enrolled 292 patients with ACS. Plasma concentrations of TMAO were measured during the hospitalization for ACS. Observation period lasted 7 years in the median. Adjusted Cox-regression analysis was used for prediction of mortality.
Results
ROC curve analysis revealed that increasing concentrations of TMAO levels assessed at the time point of ACS significantly predicted the risk of CV mortality (c-index=0.78, p<0.001). The cut-off value of >4 μmol/L, labeled as high TMAO level (23% of study population), provided the greatest sum of sensitivity (85%) and specificity (80%) for the prediction of CV mortality and was associated with a positive predictive value of 16% and a negative predictive value of 99%. A multivariate Cox regression model revealed that high TMAO level was a strong and independent predictor of CV death (HR=11.62, 95% CI: 2.26–59.67; p=0.003). High TMAO levels as compared with low TMAO levels were associated with the highest risk of CV death in a subpopulation of patients with diabetes mellitus (27.3% vs 2.6%; p=0.004). Although increasing TMAO levels were also significantly associated with all-cause mortality, their estimates for diagnostic accuracy were low.
Conclusions
High TMAO level is a strong and independent predictor of long-term CV mortality among patients presenting with ACS. TMAO concentration of 4 μmol/L may be a cut-off value for prognosis of ACS patients.
Funding Acknowledgement
Type of funding sources: None. Figure 1. Kaplan-Meier curvesTable 1
Collapse
Affiliation(s)
- C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J Jarosz-Popek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - D Jakubik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Wolska
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Nowak
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Ufnal
- Medical University of Warsaw, Department of Experimental Physiology and Pathophysiology, Laboratory of Centre for Preclinical Rese, Warsaw, Poland
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Toma
- Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria
| | - I Lang
- Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria
| | - J M Siller-Matula
- Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria
| | | |
Collapse
|
7
|
Eyileten C, Wicik Z, Jarosz-Popek J, Czajka P, Fitas A, Wolska M, Nowak A, Jakubik D, Postula M, Pare G, De Rosa S, Czlonkowska A, Mirowska-Guzel D. Fingerprint of novel circulating microRNAs identify patients with stroke-embolic stroke of undetermined source. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Stroke is the second-most common cause of death worldwide. Circulating levels of selected microRNAs (miRNAs) were found to be modulated both in animal experimental models and in patients with stroke, opening up new avenues for the identification of more effective and specific biomarkers to identify and risk-stratify stroke patients. Aim of the present study is to identify all circulating miRNAs that are modulated in patients with stroke, to select specific miRNAs to be used as disease biomarkers to improve prognosis.
Methods
48 patients with stroke- ESUS were involved in the study. We have divided the patient groups based on patients who had a second stroke or TIA and did not have (safety vs safety control). Total RNA was extracted from plasma samples quality of extracted material was assessed using a fluorometric electrophoretic assay. MiRNA profiling was performed using the Affymetrix platform using. Statistical analysis was performed in TAC software. Additional analyses were performed in and R using Signal information obtained from the TAC output. We performed the following tests using log2 transformed data and all comparison groups (A-F). We performed additional FDR correction, logistic regression, Mann-whitney test t-test depending if variances were equal or differing. We calculated Area under the curve using ROCp R package. Scores were ranging from 0–1. Co-expression analysis to identify genes authentically expressed was performed using Spearman correlation (cutoff=0.9, Rpval=0.05). In order to identify the targets of DE miRNAs we used our wizbionet R package and previously developed pipelines [1,2]. We performed target screening using multimiR package, selecting top 20% predictions from all available databases.
Results
MiR-4786, miR-1205, miR-548ar-3p and miR-518e-3p were found the most differentially expressed miRNAs between the groups. So far, miR-4786 was studied only in patients with acute leukemia [3]. Several studies showed the importance of miR-1205 in cell carcinoma and ovarian cancer progression [4]. Moreover, so far only one study showed the regulation of miR-548ar-3p in breast cancer [5]. Finally only one study showed the alteration of miR-518e-3p in Parkinsons disease patients [6]. Besides, our enrichment analysis showed Interleukin-2 signaling pathway, Lipid and lipoprotein metabolism, BDNF signaling pathway, MAPK signaling pathway, Intellectual Disability, Alzheimer's Disease are significantly related to ESUS- patients.
Conclusions
Any of those miRNAs were never studied in stroke before, our results identified several novel circulating prognostic biomarkers miRNAs that are down- of up-regulated in ESUS-stroke patients (who had only one vs multiple stroke). Among those several miRNAs were identified that are known to play a role in the pathophysiology of neurovascular diseases, paving the way to a new class of smart pathophysiology-based biomarkers in stroke.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Polish National Science Center OPUS Figure 1Figure 2
Collapse
Affiliation(s)
- C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - Z Wicik
- Universidade Federal do ABC, Centro de Matemática, Computação e Cognição,, Sao Paulo, Brazil
| | - J Jarosz-Popek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Wolska
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Nowak
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - D Jakubik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - G Pare
- McMaster University, Population Health Research Institute David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Canada
| | - S De Rosa
- Magna Graecia University of Catanzaro, Division of Cardiology, Department of Medical and Surgical Sciences, Catanzaro, Italy
| | - A Czlonkowska
- Institute of Psychiatry and Neurology, 2nd Department of Neurology, Warsaw, Poland
| | - D Mirowska-Guzel
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | | |
Collapse
|
8
|
Eyileten C, Pordzik J, Jakubik D, Czajka P, Wolska M, Jarosz-Popek J, Fitas A, Nowak A, De Rosa S, Gasecka A, Cieslicka-Kaplon A, Siller-Matula J, Postula M. Increased Let-7e expression is associated with long-term all-cause mortality and antiplatelet treatment in patients with type 2 diabetes mellitus. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In the light of growing prevalence of type 2 diabetes mellitus (T2DM), efforts are made to discover novel biomarkers. MicroRNAs (miRNAs-miR) are non-coding RNAs used in various processes involved in regulating gene expression which play a role in platelet function.
Purpose
To analyze the ability of platelet-derived miRNAs in prediction of mortality and response to antiplatelet treatment among T2DM-patients.
Methods
252 diabetic subjects were enrolled and were receiving either acetylsalicylic acid (ASA) 75mg (65%) or 150 mg (15%) or clopidogrel (19%). Plasma miR-126, miR-223, miR-125a-3p and Let-7e expressions were assessed by qRT-PCR and compared between the patients who survived and those who died. Median observation time was 5.9 years. Adjusted Cox-regression analysis was used for prediction of mortality. Differential miRNAs expression due to different antiplatelet treatment was analyzed.
Results
ROC curve analysis revealed increasing concentrations of miR-126, Let-7e and miR-125a-3p levels had a diagnostic ability for prediction of long-term all-cause mortality (c-index=0.75, p<0.001; 0.72, p<0.001; 0.72, p=0.001, respectively). Multivariate Cox regression model revealed high miR-126 and Let-7e expressions which were strong and independent predictors of all-cause long-term mortality (HR=5.08, 95% CI: 1.92–13.43; p=0.001; HR=5.94, 95% CI: 1.98–17.79; p=0.001,respectively). After including all miRNAs into one multivariate Cox regression model, only Let-7e was predictive of future occurrence of long-term all-cause death (HR=7.83, 95% CI: 1.2–51.1; p=0.032). MiR-126, Let-7e and miR-223 expressions in the clopidogrel group were significantly higher than in the ASA group (p=0.014; p=0.013; p=0.028, respectively).
Conclusions
Let-7e expression is a strong and independent predictor of long-term all-cause mortality among patients with T2DM. MiR-223, miR-126 and Let-7e present significant interactions with antiplatelet treatment and clinical outcomes.
Funding Acknowledgement
Type of funding sources: None. Figure 1Table 1
Collapse
Affiliation(s)
- C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J Pordzik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - D Jakubik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Wolska
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J Jarosz-Popek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Nowak
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - S De Rosa
- Magna Graecia University of Catanzaro, Division of Cardiology, Department of Medical and Surgical Sciences, Catanzaro, Italy
| | - A Gasecka
- Medical University of Warsaw, 1st Chair and Department of Cardiology, Warsaw, Poland
| | - A Cieslicka-Kaplon
- Medical University of Warsaw, 1st Chair and Department of Cardiology, Warsaw, Poland
| | - J Siller-Matula
- Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | | |
Collapse
|
9
|
Eyileten C, Fitas A, Jarosz-Popek J, Adem T, Jakubik D, Wolska M, Czajka P, Postula M, Nowak A, Gasecka A. MicroRNA-223 might be a predictive biomarker for major adverse cardiovascular events prognosis in patients undergoing transcatheter aortic valve implantation procedure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Transcatheter aortic valve implantation (TAVI) is an emerging invasive therapeutic strategy for patients with severe aortic stenosis (AS) significantly enhancing not only quality-of-life measures but also improving short-and long-term survival rates.
Purpose
For these purposes we aimed to analyze correlation between expression levels of platelet-derived microRNAs in patients with heart failure (HF) due to AS who underwent TAVI procedure and assess their association with primary major adverse cardiac events (MACE) defined by all cause mortality and secondary MACE defined as cardiovascular mortality, ischemic stroke, and non-fatal myocardial infarction.
Methods
61 patients before and after the TAVI procedure were included. PlasmaRNA was extracted by mirVANA PARIS Kit and quality of RNA was assessed by fluorometric assay. GEP analysis was performed using the Clariom D pico chips, analyzed on the Affymetrix platform. RT-PCR was performed in order to validate the miRNAs in 61 patients by using the Taqman advanced protocol. MiRNA related to platelet function/antiplatelet treatment were chosen among those with the most relevant modulation between the groups. Wilcoxon test was performed for miRNAs comparison before and after TAVI. Calculations were performed using SPSS version 22.0, p<0.05 (IBM Corporation, Chicago, USA).
Results
We have found that miR-223, miR-125b and miR-125a were significantly increased in patients after the TAVI procedure. ROC analysis showed that increased miR-223 expression after the TAVI procedure might slightly have protective value against MACE outcome.
Conclusions
Our analysis showed alteration of circulating miRNAs after the TAVI procedure and miR-223 might have a predictive value for MACE prognosis in patients with HF due to AS who underwent TAVI procedure.
Acknowledgment
I-COMET research team
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- C Eyileten
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Fitas
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - J Jarosz-Popek
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - T Adem
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - D Jakubik
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Wolska
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - P Czajka
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - M Postula
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Nowak
- Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharma, Warsaw, Poland
| | - A Gasecka
- Medical University of Warsaw, 1st Chair and Department of Cardiology, Warsaw, Poland
| | | |
Collapse
|
10
|
Czajka P, Fitas A, Jakubik D, Eyileten C, Gasecka A, Wicik Z, Siller-Matula JM, Filipiak KJ, Postula M. MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. Front Physiol 2021; 12:652579. [PMID: 33935804 PMCID: PMC8081881 DOI: 10.3389/fphys.2021.652579] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 03/22/2021] [Indexed: 11/25/2022] Open
Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.
Collapse
Affiliation(s)
- Pamela Czajka
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland
| | - Daniel Jakubik
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland
| | - Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland
| | - Aleksandra Gasecka
- First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
| | - Zofia Wicik
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland.,Centro de Matemática, Computação e Cognição, Universidade Federal do ABC, São Paulo, Brazil
| | - Jolanta M Siller-Matula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland.,Department of Cardiology, Medical University of Vienna, Vienna, Austria
| | - Krzysztof J Filipiak
- First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland
| |
Collapse
|
11
|
Jakubik D, Fitas A, Eyileten C, Jarosz-Popek J, Nowak A, Czajka P, Wicik Z, Sourij H, Siller-Matula JM, De Rosa S, Postula M. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. Cardiovasc Diabetol 2021; 20:55. [PMID: 33639953 PMCID: PMC7916283 DOI: 10.1186/s12933-021-01245-2] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 02/13/2021] [Indexed: 02/08/2023] Open
Abstract
The epidemic of diabetes mellitus (DM) necessitates the development of novel therapeutic and preventative strategies to attenuate complications of this debilitating disease. Diabetic cardiomyopathy (DCM) is a frequent disorder affecting individuals diagnosed with DM characterized by left ventricular hypertrophy, diastolic and systolic dysfunction and myocardial fibrosis in the absence of other heart diseases. Progression of DCM is associated with impaired cardiac insulin metabolic signaling, increased oxidative stress, impaired mitochondrial and cardiomyocyte calcium metabolism, and inflammation. Various non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), as well as their target genes are implicated in the complex pathophysiology of DCM. It has been demonstrated that miRNAs and lncRNAs play an important role in maintaining homeostasis through regulation of multiple genes, thus they attract substantial scientific interest as biomarkers for diagnosis, prognosis and as a potential therapeutic strategy in DM complications. This article will review the different miRNAs and lncRNA studied in the context of DM, including type 1 and type 2 diabetes and the contribution of pathophysiological mechanisms including inflammatory response, oxidative stress, apoptosis, hypertrophy and fibrosis to the development of DCM .
Collapse
Affiliation(s)
- Daniel Jakubik
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland
| | - Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland
| | - Joanna Jarosz-Popek
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland.,Doctoral School, Medical University of Warsaw, 02-091, Warsaw, Poland
| | - Anna Nowak
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland
| | - Pamela Czajka
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland
| | - Zofia Wicik
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland.,Centro de Matemática, Computação e Cognição, Universidade Federal Do ABC, São Paulo, Brazil
| | - Harald Sourij
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Jolanta M Siller-Matula
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland.,Department of Cardiology, Medical University of Vienna, Vienna, Austria
| | - Salvatore De Rosa
- Division of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy.,Cardiovascular Research Center, "Magna Graecia" University, Catanzaro, Italy
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B Str., 02-097, Warsaw, Poland.
| |
Collapse
|
12
|
Zareba L, Fitas A, Wolska M, Junger E, Eyileten C, Wicik Z, De Rosa S, Siller-Matula JM, Postula M. MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets. Cardiol Clin 2020; 38:601-617. [PMID: 33036721 DOI: 10.1016/j.ccl.2020.07.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Noncoding RNAs (ncRNAs), including long noncoding RNAs and microRNAs, play an important role in coronary artery disease onset and progression. The ability of ncRNAs to simultaneously regulate many target genes allows them to modulate various key processes involved in atherosclerosis, including lipid metabolism, smooth muscle cell proliferation, autophagy, and foam cell formation. This review focuses on the therapeutic potential of the most important ncRNAs in coronary artery disease. Moreover, various other promising microRNAs and long noncoding RNAs that attract substantial scientific interest as potential therapeutic targets in coronary artery disease and merit further investigation are presented.
Collapse
Affiliation(s)
- Lukasz Zareba
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland
| | - Alex Fitas
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland
| | - Marta Wolska
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland
| | - Eva Junger
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland
| | - Ceren Eyileten
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland
| | - Zofia Wicik
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland; Centro de Matemática, Computação e Cognição, Universidade Federal do ABC, Alameda da Universidade, s/n-Anchieta, São Paulo 09606-045, Brazil
| | - Salvatore De Rosa
- Division of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, Viale Europa, Catanzaro 88100, Italy
| | - Jolanta M Siller-Matula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Austria
| | - Marek Postula
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B Str., Warsaw 02-097, Poland; Longevity Center, Warsaw, Poland.
| |
Collapse
|